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ABSTRACT
Background: The increasing prevalence of bacterial infections that are resistant to
antibiotic treatment has caused the scientific and medical communities to look for
alternate remedies aimed at prevention and treatment. In addition to researching
novel antimicrobials, there has also been much interest in revisiting some of the
earliest therapies used by man. One such antimicrobial is silver; its use stretches
back to the ancient Greeks but interest in its medicinal properties has increased in
recent years due to the rise in antibiotic resistance. Currently antimicrobial silver is
found in everything from lunch boxes to medical device implants. Though much is
claimed about the antimicrobial efficacy of silver salts the research in this area is
mixed.
Methods: Herein we investigated the efficacy of silver acetate against a carbapenem
resistant strain of Acinetobacter baumannii to determine the in vitro activity of
this silver salt against a World Health Organisation designated category I critical
pathogen. Furthermore, we use the Galleria mellonella larvae model to assess
toxicity of the compound and its efficacy in treating infections in a live host.
Results: We found that silver acetate can be delivered safely to Galleria at
medically relevant and antimicrobial levels without detriment to the larvae and that
administration of silver acetate to an infection model significantly improved survival.
This demonstrates the selective toxicity of silver acetate for bacterial pathogens
but also highlights the need for administration of well-defined doses of the
antimicrobial to provide an efficacious treatment.
Subjects Entomology, Microbiology, Toxicology
Keywords Acinetobacter baumannii, Galleria mellonella, Silver acetate, Infection model,
Antimicrobial
INTRODUCTION
The use of silver as an antimicrobial has been described throughout recorded history
(Alexander, 2009) and though its popularity waned with the development and widespread
use of antibiotics from the 1940’s, the increasing global prevalence of antibiotic resistance
amongst bacterial pathogens has reignited interest in this ancient remedy. Currently
silver, in different forms, is used to reduce the incidence and severity of infection in wound
treatment via the application of topical suspensions and dressings (Atiyeh et al., 2007;
Politano et al., 2013) as well as being incorporated into indwelling medical devices such as
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vascular access grafts from companies including B. Braun Medical Ltd. (B. Braun
Melsungen AG, https://www.bbraun.com/en/products/b/silver-graft.html) and Getinge
AB. (Getinge AB, https://www.getinge.com/int/product-catalog/intergard-silver/).
Despite its apparent popularity as an antimicrobial, the efficacy of silver treatments has
met with mixed results in the research community (Chopra, 2007; Politano et al., 2013)
and manufacturer efficacy claims are often difficult to verify due to a lack of access to raw
data. Given these limitations on determination of antimicrobial activity, there is clear
evidence that more independent data is needed to better understand the antibacterial
activity of silver compounds currently in use for treatment of infection. Herein we
investigated the efficacy of a commercially used silver salt, silver acetate, against a
WHO priority 1: critical pathogen; carbapenem-resistant Acinetobacter baumannii.
Acinetobacter baumannii is a Gram-negative nosocomial pathogen. Its success as a
nosocomial pathogen can be attributed to multiple factors including; the bacterium’s
ability to adhere to and thrive on abiotic and biotic surfaces, its capacity to form biofilms
and its multi-drug resistance arising from a variety of mechanisms (McQueary & Actis,
2011; Longo, Vuotto & Donelli, 2014). Patients in intensive care units are most vulnerable
to A. baumannii infection with manifestations varying due to point of entry including
urinary tract infections, bacteraemia, secondary meningitis, wound infections and most
commonly, ventilator associated pneumonia (Coenye et al., 2008; McQueary & Actis,
2011). Many of these infections, such as those on catheters (Thallinger et al., 2014) and
endotracheal tubing (Raad et al., 2011), are caused by the formation of biofilms increasing
the difficulty for clinicians to clear the pathogen.
Acinetobacter baumannii, an ESKAPE pathogen (Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, A. baumannii, Pseudomonas aeruginosa and Enterobacter
species), is capable of multiple antibiotic resistances with many nosocomial strains
isolated being multi-drug resistant and several strains identified as being pan-drug
resistant (Kim et al., 2014). This led to the World Health Organisation assigning the
carbapenem resistant strains of this species to the list of bacteria that pose the greatest
threat to human health, specifically these strains are designated as Category I: critical,
with the World Health Organisation encouraging prioritisation of research towards
finding new means to combat infections caused by these strains (Tacconelli & Magrini,
2017). Despite the obvious threat posed to human health by this pathogen, A. baumannii is
the least studied of the ESKAPE pathogens and little research has been undertaken to
understand the efficacy of silver salts such as silver acetate against this organism.
A. baumannii strains have numerous mechanisms of antibiotic resistance including
intrinsic resistance, enzymes that alter the antibiotic thereby reducing or eliminating
activity, efflux pumps, modification of drug targets and permeability defects (Lin & Lan,
2014).
Due to the rapid emergence of multi-drug resistant and pan-drug resistant strains
of A. baumannii across the globe there is an increasing interest in development of
antimicrobials including silver acetate as a potential means to combat these infections
(World Health Organisation, 2015). Silver has a long history of antimicrobial activity due
to the ionisation of silver in water and bodily fluids to produce the silver ion, Ag+
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(Lansdown, 2006; Marx & Barillo, 2014). Silver ions have a widespread effect on bacterial
cells, firstly by interacting with residues on the cell membrane including disulphides and
phosphates to stimulate endocytosis of the ions. Once inside the cell, the ionic silver
interacts with cell membrane enzymes to cause denaturation of the cell envelope and
interacts with other vital enzymes that control respiration and replication (Marx & Barillo,
2014). Importantly, due to the multiple targets of silver within a bacterial cell the
emergence of resistance is slow (Marx & Barillo, 2014).
Also important in developing efficacious infection treatments is the selective toxicity
of the antimicrobial. Silver ions are thought to have low toxicity in the human body,
often their accumulation after administration is transitory with minimal toxicity
(Lansdown & Williams, 2004; Lansdown, 2006). Although silver ions have been found
to accumulate in the organs and tissues of rats and humans at high doses (Drake &
Hazelwood, 2005; Loeschner et al., 2011) and permanent accumulation of silver can
occur in the cornea and skin after prolonged exposure, this is not thought to be life
threatening (Lansdown & Williams, 2004; Lansdown, 2006). The uptake of silver into the
body during silver treatment has not been investigated in depth, however clinical studies
have shown increased absorption through partial-thickness burns (Wang et al., 1985;
Boosalis et al., 1987; Coombs et al., 1992).
One means of better understanding host toxicity without the need for human or animal
trials that has gained popularity in recent years utilises Galleria mellonella larvae models.
Galleria mellonella, commonly known as the greater wax moth, are insects within the
order lepidoptera. Their larvae have a rudimentary immune system that can be said to
mimic the mammalian immune system (Hernandez et al., 2019). By comparison to
mammalian models, larvae are cheap to source in large numbers and do not require ethical
approval. They are easy to manipulate experimentally, can survive in temperatures suitable
for investigation of human pathogens (25–37 C) and require no specialised equipment
for maintenance. To ensure standardisation amongst assays larvae should be obtained
from reputable suppliers (e.g. Bio Systems Technology TruLarvTM) that guarantee the
larvae are not treated with antibiotics and their growth conditions upon receipt have
been standardised, so that larvae arrive in the same life stage with similar approximate
dimensions. This makes the use of Galleria larvae in simple animal models of toxicity,
infection and antimicrobial treatment highly favourable (Tsai, Loh & Proft, 2016; Pereira
et al., 2018; Hernandez et al., 2019).
The aims of this study were to determine antimicrobial efficacy of silver acetate against
A. baumannii in vitro, to identify the concentration of silver acetate that causes toxicity
in the G. mellonella model and to determine whether this antimicrobial can rescue the
larvae from lethal A. baumannii infection.
MATERIALS AND METHODS
Strains and culture methods for A. baumannii
Strains were obtained from the American Type Culture Collection (ATCC), USA and the
National Collection of Type Cultures (NCTC), UK. Strains were stored at −80 C as 20%
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glycerol stocks and were cultured on Mueller–Hinton agar and broth (Sigma Aldrich Ltd,
UK) at 37 C unless otherwise stated.
Silver acetate
Silver acetate was purchased from Sigma–Aldrich Ltd. Silver acetate stocks were prepared
by dissolving in sterile distilled water and were stored protected from light at room
temperature.
Minimum inhibitory and bactericidal concentration assays
Overnight cultures of A. baumannii were diluted to OD600 = 0.1 in sterile phosphate
buffered saline (PBS). Wells of 96-well plates were filled with 100 µl Mueller–Hinton broth
and silver acetate ((1,000 mg L−1) final) or meropenem ((10 mg L−1) final) was added
to wells in column one as appropriate. Two-fold serial dilutions were performed
across the silver acetate plates while meropenem was diluted in 1 mg mL−1 increments.
Subsequently 10 µl diluted overnight culture was added to all test and positive control
wells. Negative growth controls contained broth only. Plates were incubated statically at
37 C for 18 h in aerobic conditions. The minimum inhibitory concentration (MIC) was
determined as the lowest concentration of compound where no visible growth was
observed. Minimum bactericidal concentrations (MBCs) were determined by plating out
10 µl spots of culture in triplicate onto Mueller–Hinton agar from every well where no
growth was observed in the MIC assay. The MBC was determined as the lowest
concentration of compound where growth could not be recovered.
Growth in the presence of silver acetate
Mueller–Hinton broth (0.9 ml) was added to the wells of a 24-well plate, with a further
addition of 0.1 ml bacterial overnight culture diluted to OD600nm = 0.5. The plate was
incubated at 37 C with orbital shaking (4 mm) in a Biotek citation 3 imaging reader
until absorbance of wells reached an OD600nm of 0.3. Silver acetate was added to wells at
final concentrations of 15.6, 7.80, 3.91, 1.95, 0.98 and 0 mg L−1. Growth was monitored
every 20 min for 24 h and viability was measured every hour for the first 8 h.
Biofilm assay
Overnight cultures of A. baumannii were diluted to an OD600 = 0.5 in sterile PBS. Wells of
24-well plates were filled with one ml Mueller–Hinton broth and silver acetate was added
to wells in column one to a final concentration of 7.8 mg L−1. Two-fold serial dilutions
were performed across the plate. Subsequently 100 µl diluted overnight culture was added
to all test wells and positive control wells. Negative controls contained broth only. Plates
were incubated statically at 37 C for 18 h in aerobic conditions. Thereafter broth was
aspirated, and biofilms were washed three times in one ml sterile PBS. Wells were air
dried and stained with 500 µl of 0.1 % (v/v) crystal violet for 1 h. Stain was then removed,
and wells were washed with PBS. Stain bound to the biofilm was solubilised with 200 µl
of ethanol. The OD540 of each well was measured using a BioTek
 CytationTM 3 cell
imaging multi-mode reader.
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Galleria mellonella
Galleria mellonella larvae were purchased from TruLarvTM, Biosystems Technology,
Exeter, UK and were used immediately upon arrival. Larvae selected for use were healthy
as demonstrated by a melanisation score of four and moving freely without stimulation.
For all incubations G. melonella were placed in vented petri dishes on WhatmanTM
filter paper. For each experiment, groups of 10 larvae were used per condition and all
experiments were repeated a minimum of three times on different dates ensuring that each
condition was tested with a minimum of 30 larvae from different batches of Galleria.
Inoculum testing
Cultures of A. baumannii NCTC 13302 were incubated overnight, then washed in PBS
to remove residual media and diluted to the appropriate concentration. Healthy larvae
were infected with bacterial cultures, equating to 1.7 × 102, 1.7 × 103, 1.7 × 104, 1.7 × 105,
1.7 × 106, or 1.7 × 107 CFU per larvae in a final volume of 10 µl by injection into the
last left proleg. Control groups were injected with 10 µl PBS or were not injected. Larvae
were incubated at 37 C for four days and were monitored for melanisation score and
survival every 24 h post-injection.
Toxicity assays
Healthy larvae were injected in the last left proleg with 10 µl water containing silver acetate
at a final concentration of 1.25, 2.5, 5, 10, 20, 40 or 80 mg kg−1 animal weight. Control
groups were injected with 10 µl water or were not injected. Larvae were incubated for
four days at 37 C with survival and melanisation scoring carried out every 24 h
post-injection.
Treatment assays
Cultures of A. baumannii NCTC 13302 were incubated overnight, then washed in
PBS and diluted to the appropriate concentration. Healthy larvae were injected with
A. baumannii that equated to 1.7 × 105 or 1.7 × 106 CFU per larvae in the last left
proleg. Following a 30 min incubation at 37 C, a second injection was administered
containing 0, 10 or 20 mg kg−1 animal weight of silver acetate into the last right proleg.
Larvae were incubated for four days at 37 C with survival and melanisation scoring
carried out every 24 h post-injection.
Statistical analyses
Statistical analysis to determine the significance of difference in Galleria mellonella larval
survival between different conditions used the Log rank (Mantel-cox) test. Analysis of biofilm
formation and larval health scores used two-way ANOVAwith Tukey’s multiple comparison.
RESULTS
Silver acetate demonstrates antimicrobial activity against A. baumannii
To first demonstrate the antimicrobial activity of silver acetate five strains of A. baumannii
were tested to determine the minimum inhibitory and bactericidal concentrations of
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this silver salt for each strain. The MIC of silver acetate was found to be 4.56 mg L−1 or
lower for all strains tested, demonstrating the antibacterial activity of silver acetate against
this species (Table 1).
To confirm whether the mechanism of antimicrobial activity of silver acetate was
growth inhibition or killing in this species; MBC assays were performed. In all strains the
MBC did not significantly differ from the MIC for silver acetate suggesting a bactericidal
mechanism of action (Table 1).
To evaluate the antimicrobial activity of silver acetate against A. baumannii to a greater
extent theWHO priority 1: critical pathogen strain NCTC 13302 was chosen for further study.
The permanence of silver acetate toxicity against exponentially
growing A. baumannii is concentration dependent
Frequently antibiotic intervention commences when the infection is established, and
bacterial load is high with the pathogen actively growing. Considering this we sought to
determine how exposure of exponentially growing bacteria to silver acetate at a range of
concentrations impacted growth and viability.
Exponentially growing cultures of A. baumannii NCTC 13302 were established before
the addition of varying concentrations of silver acetate that centered around the MIC for
this strain. When cultures were exposed to concentrations of silver acetate below the
recorded MIC (3.91 mg L−1) no significant decrease in growth was observed compared
to the control (Figs. 1A and 1B). However, at concentrations above the MIC (7.8 and
15.6 mg L−1) loss of growth was rapid and permanent (Figs. 1D and 1E) Interestingly,
exponentially growing cultures exposed to the MIC of silver acetate (3.91 mg L−1) showed a
biphasic effect with inhibition of growth within the first 10 h after exposure but growth
recovery over the following 14 h (Fig. 1C).
To understand whether the silver acetate mechanism of action was bactericidal as
suggested by the MIC and MBC assays (Table 1) viability assays were conducted on the
cultures immediately prior to and at regular intervals after addition of silver acetate.
Viability did not appear to be impacted when silver acetate was administered below the
Table 1 Minimum inhibitory and bactericidal concentrations for silver acetate against a range of A. baumannii strains demonstrates
significant antimicrobial activity. Standard MIC and MBC assays were performed against a range of A. baumannii strains grown in Mueller–
Hinton Broth in a 96-well plate. Where the MBC appears to be higher than the MIC statistical analysis showed no significant difference (paired
T-test P = 0.2839, N = 3 ± SD). Meropenem MIC’s determined for comparison to silver activity.
Bacterial/strain Type/origin Silver acetate Meropenem
MIC mg L−1 (SD) MBC mg L−1 (SD) MIC mg L−1
(SD)
ATCC 17978 Clinical isolate 4.56 (1.59) 9.11 (3.19) 0.194 (0.0659)
NCTC 12156 Type strain 3.91 (0) 7.81 (0) 0.556 (0.110)
NCTC 13301 Type D carbapenemase reference strain OXA-23 3.91 (0) 6.64 (2.62) >10 (0)
NCTC 13302 Type D carbapenemase reference strain OXA-25 3.91 (0) 7.81 (0) >10 (0)
NCTC 13305 Type D carbapenemase reference strain OXA-58 4.56 (1.59) 13.03 (9.49) 5.47 (1.64))
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MIC but when administered at a concentration of double the MIC or higher there was a
significant decrease in viability from two hours, with complete loss of viability at 6 h
(Fig. 2). When exposed to silver acetate at the MIC, A. baumannii viability decreased
10-fold after two hours and 65-fold by 8 h, however these were modest decreases in
viability that were recovered by 24 h (Fig. 2) suggesting that relatively few cells were killed
in cultures exposed to this concentration of silver acetate and highlighting the need for
appropriate dosing when using silver salts as antimicrobial agents.
Biofilm formation in A. baumannii is inhibited by silver acetate
Biofilm formation is a major cause of infection and mortality. A. baumannii is known
to readily form biofilms under numerous clinically relevant conditions, therefore we

















































































Figure 1 The growth inhibition of Acinetobacter baumannii exposed to silver acetate is
concentration dependent. Silver acetate was added to exponentially growing cultures at final con-
centrations of (A) 0.98, (B) 1.95, (C) 3.91, (D) 7.81 and (E) 15.60 mg L−1. Cultures were incubated at
37 C with shaking and growth monitored via absorbance (OD600) every 20 min for 24 h. (F) Panel shows
growth in the presence of all concentrations of silver acetate for comparison. N = 3, error bars are omitted
for clarity, but standard deviations were all within the range 0.0006–0.1664.
Full-size DOI: 10.7717/peerj.11196/fig-1
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Cultures of A. baumannii were incubated statically in a 24-well plate at 37 C for 18 h in
Mueller–Hinton broth containing concentrations of silver acetate ranging from 0 to
7.81 mg L−1. After incubation the amount of biofilm formation and number of viable
cells were determined using crystal violet staining and viability assays respectively.
At concentrations below the MIC, there was no significant difference in the amount of
biofilm formed compared to the negative control. However, when bacteria were incubated
with higher concentrations of silver acetate (3.91–7.81 mg L−), there was a significant
reduction in biofilm formation (<0.0001, Fig. 3A). Enumeration of viable cells within the
biofilms also showed no significant difference between the viability of cells exposed to
silver acetate concentrations below the MIC compared to the negative control. At higher
silver salt concentrations (3.91–7.81 mg L−) survival was reduced significantly (P < 0.005,
Fig. 3B).
Infection of G. mellonella with A. baumannii causes a lethal infection
Over the past decade G. mellonella larvae have become an established model for analysing
the virulence and pathogenesis of human bacterial pathogens and in the testing of novel
antimicrobial compounds. Initial testing in this study sought to determine the virulence
of A. baumannii strain NCTC 13302 using a G. mellonella infection model. Here, the
larvae were divided into groups and injected in the last left proleg with 10 µl of the
appropriate number of bacteria (1.7 × 102–1.7 × 107 cells per larvae), PBS (vehicle control)
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Figure 2 The bactericidal activity of silver acetate against exponentially growing Acinetobacter
baumannii is concentration and time dependent. Batch cultures of A. baumannii were grown at
37 C with shaking to early exponential phase when silver acetate was added at final concentrations of 0,
0.98, 1.95, 3.91, 7.81 or 15.60 mg L−1 (t = 0 h). Cultures were incubated for a further 24 h with viability
determined at two-hour intervals to 8 h post-exposure (t = 2–8 h) and at 24 h. N = 3 ± SEM.
Full-size DOI: 10.7717/peerj.11196/fig-2
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or were not injected (no injection control). The larvae we incubated at 37 C and
monitored for changes in health every 24 h over the following four days. To ensure that
batch variations did not bias the results, this experiment was repeated three times with
different batches of larvae purchased on different dates. In total, 30 larvae per condition
were tested.
Figure 4A shows survival of the larvae over four days, with the lowest concentration of
bacteria injected causing no significant difference in larval death compared to the negative
controls. The highest concentration of bacteria killed all larvae within 24–48 h and
intermediate concentrations caused significantly different levels of killing over four days
(P < 0.0001). The immune system of G. mellonella includes a cellular response called
melanisation. This cellular response is used to trap microbes, but also makes it possible to
track the immune response and health of the larvae via visible colour change (Wojda,
2017). Melanisation of the larvae was monitored as an indicator of health and supported
the survival data with decreased health observed with increased bacterial load and
significant variation in health across the higher concentrations of bacteria in comparison










































































Figure 3 Biofilm production is significantly reduced in the presence of silver acetate. A. baumannii
cultures were incubated statically in Mueller-Hinton broth at 37 C in 24-well plates in the presence of
varying concentrations of silver acetate (0–7.81 mg L−1). (A) After incubation the wells were washed and
stained with crystal violet to determine the amount of biofilm formed (OD540). Differences in biofilm
formed between the lower (0–1.95 mg L−1) and higher (3.91–7.81 mg L−1) concentrations of silver acetate
were highly significant (ANOVA and Tukeys multiple comparison test, P < 0.0001). (B) After
incubation, biofilms were disaggregated and bacterial viability was determined. Significant differences in
biofilm formation were observed between the lowest (0–0.488 mg L−1) and highest concentrations of silver
acetate (3.9–7.8 mg L−1, ANOVA and Tukey’s multiple comparison, P = 0.0005–0.003) N = 3 ± SEM.
Full-size DOI: 10.7717/peerj.11196/fig-3
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A range of silver acetate concentrations commonly used in antibiotic
therapy shows minimal toxicity to G. mellonella
For an antimicrobial to be appropriate for therapy it should display two key features:
antimicrobial activity against the target pathogen(s) and minimal toxicity towards the host.
We used a G. mellonella model to determine the toxicity of silver acetate towards the host
over a variety of clinically relevant concentrations.
Galleria were divided into groups and were injected with silver acetate in concentrations
ranging from 1.25 to 80 mg kg−1 of animal weight (approximately 0–24 µg per larvae).
Negative control groups included larvae that were injected with water or were not injected.
The experiment was repeated in temporally spaced triplicate to account for batch to
batch variations in the larvae and collectively 30 larvae were tested per condition.
The data demonstrated that only the 80 mg kg−1 dosage of silver acetate caused
persistent larval death of ~10% (Fig. 5A), although no significant difference between
the survival of larvae at the different concentrations was observed (P = 0.0524).
The melanisation scores showed that only larvae exposed to the highest concentration
of silver acetate produced visible melanisation (Fig. 5B). A significant difference in
melanisation developed between the 80 mg kg−1 injected larvae and no silver acetate
controls from 72 h onwards.
Figure 4 Infection of Galleria mellonella larvae with varying concentrations of Acinetobacter
baumannii causes changes in health and lethality. Groups of G. mellonella larvae were injected with
10 µl of A. baumannii containing between 1.7 × 102 and 1.7 × 107 cells per larvae, control groups were
injected with PBS or were not injected. (A) Larval survival was monitored every 24 h for 96 h post-
injection. The dotted line corresponds to 80% larval death (P < 0.0001, N = 30 larvae per condition)
(B) Melanisation was recorded for all larvae every 24 h for 96 h post-injection (P = 0.0423,
P = 0.001–0.0063, P = 0.0006, P < 0.0001, N = 30 larvae per concentration, ±SEM). (C and D)
Standard melanisation scoring. Full-size DOI: 10.7717/peerj.11196/fig-4
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Treatment of A. baumannii infection with silver acetate causes
increased survival
To address whether silver acetate is an effective antimicrobial against infection in a
G. mellonella infection model, larvae were injected with concentrations of bacteria that
would cause significant death within four days without intervention (Fig. 3, 1.7 × 105
and 1.7 × 106 cells per larvae). Thirty minutes post-infection the larvae were administered
with either 10 or 20 mg kg−1 silver acetate, both concentrations having demonstrated
minimal toxicity towards Galleria (Fig. 5). As with previous experiments the Galleria
were tested in groups of ten larvae. To ensure statistical significance of the results and to
account for batch to batch variations with the larvae this experiment was repeated seven
times with a total of 70 larvae tested per condition across all repeats.
Larvae injected with the ~105 bacterial cells were better able to survive than larvae
injected with the ~106 bacterial cells in all conditions. Larvae treated with either
concentration of silver acetate showed significant increase in survival (P < 0.05, Fig. 6).
Larvae infected with the lower infectious dose of A. baumannii showed a 20% increase in
survival after treatment with silver acetate (Fig. 6A). For larvae receiving the higher
infectious dose, 10 mg kg−1 silver acetate treatment caused larval survival to increase by
31% and treatment with 20 mg kg−1 silver acetate increased larval survival by 27%
(Fig. 6B).
Correlating with the increased survival, improved larval health was also observed
when silver acetate treatment was administered (Figs. 6C and 6D). As with the infection
studies (Fig. 4) the melanisation score of larvae injected with both ~105 and ~106 bacterial
cells showed a reduction in health from 48 h. However, after silver acetate treatment of
Galleria infected with ~105 bacterial cells, differences in melanisation between the treated
and non-treated larvae became significant after 72 h (P < 0.042). For Galleria infected with
~106 bacterial cells, significant differences appeared between the non-treated larvae and
the larvae treated with both concentrations of silver acetate at 96 h (P < 0.009).
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Figure 5 A range of medically relevant silver acetate concentrations shows minimal toxicity to
Galleria mellonella. Groups of Galleria mellonella larvae were injected with 10 µl of silver acetate
between 0 and 80 mg kg−1 animal weight. (A) Larval survival was monitored every 24 h for 96 h
post-injection (N = 30 larvae per condition). (B) Melanisation was recorded for all larvae every 24 h for
96 h post-injection and assigned a standard melanisation score (P = 0.0006, N = 30 larvae per
condition, ±SEM). Full-size DOI: 10.7717/peerj.11196/fig-5
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DISCUSSION
Silver salts are incorporated into many commercially available, indwelling medical devices
to provide antimicrobial activity during implantation for protection against infection
during the time when the risk of infection is highest. Similarly, silver is also incorporated
into wound dressings to provide antimicrobial activity against infected wounds (Leaper
et al., 2012; National Institute for Helth & Care Excellence, 2020). The data presented
herein sought to gain a better understanding of the antimicrobial efficacy and host toxicity
of silver acetate to provide further insight into its potential value in infection control.
Silver acetate proved to be an effective antimicrobial in vitro for all A. baumannii strains
tested with minimal inhibitory and bactericidal concentrations in the range of many
clinically relevant antibiotics as assessed using standardised methods for determination of
MIC and MBC values (The European Committee on Antimicrobial Susceptibility Testing,
2019). This included strains with limited antibiotic resistance and those with multiple
resistances suggesting that existing antibiotic resistance mechanisms do not cause
increased resistance to silver. Additionally, these values are broadly similar to reported
MIC values for this species against silver nitrate (2.5 mg L−1, (Wan et al., 2016)) and silver
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Figure 6 Silver acetate treatment ofGalleria mellonella larvae infected with Acinetobacter baumannii
reduced lethality and improved overall health of the larvae. Groups of Galleria mellonella larvae were
injected with 10 µl of A. baumannii containing either 1.7 × 105 or 1.7 × 106 cells per larvae, 30 min
post-infection groups of larvae were administered either 10 or 20 mg kg−1 silver acetate as treatment.
N = 70 larvae per condition. (A and B) Survival and (C and D) melanisation were recorded every 24 h for
96 h post-injection. (A and B) P < 0.05. (C and D) Error bars show SEM, P = 0.0168–0.0235,
P = 0.0015–0.0089. Full-size DOI: 10.7717/peerj.11196/fig-6
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ions (3.9 mg L−1, (Vaidya et al., 2017)). This is expected due to the antimicrobial
mechanisms of silver acetate being caused by the silver ions in solution with the salt itself
being largely inert in terms of antimicrobial activity. Silver ions are able to bind to the bases
of DNA and RNA (Arakawa, Neault & Tajmir-Riahi, 2001), which is thought to be
responsible for bacterial mutation and issues with replication, however this has yet to be
proven in vivo. Silver ions cause numerous disruptions to proteins within the bacterial cell.
Silver ions can bind to sulfhydryl groups on amino acids, disrupting protein function
(Russell & Hugo, 1994), they are thought to disrupt iron-sulfur clusters (Xu & Imlay, 2012),
thiol groups and sulfhydryl-liganded metals (Morones-Ramirez et al., 2013). There is also
evidence of the role for silver in membrane disruption causing enhanced permeability
(Morones-Ramirez et al., 2013; Vazquez-Muñoz et al., 2019). With this multitude of
targets, it is perhaps unsurprising that antibiotic resistant strains are still susceptible to
silver ions. Increased bactericidal activity has been reported via the production of silver
nanoparticles. The size and shape of these silver nanoparticles play a key role in their
bactericidal activity (Pal, Tak & Song, 2007).
The issue of resistance to silver compounds developing due to widespread use has
been a topic of much debate. Whilst some research has suggested that the resistance to
silver is slow to emerge and mild due to the requirement of the bacterium to develop
resistances that nullify several of the above mentioned mechanisms of action (Marx &
Barillo, 2014), others have described various mechanisms of silver resistance that is
emerging across the globe. One such mechanism is the production of redox active
metabolites, for example the production of pyocyanin by P. aeruginosa has been
demonstrated to not only protect itself but also other species of bacteria in close proximity
to the phenazine compound (Muller, 2018). This is a concern as P. aeruginosa is frequently
isolated from polymicrobial infections. Another mechanism of silver resistance
described in the literature is the increased expression or acquisition via horizontal gene
transfer of the sil system (Hosny et al., 2019). This collection of genes primarily reduces
intracellular accumulation of silver inside the cell by expressing periplasmic proteins that
bind silver preventing further penetration into the cell and by expressing silver efflux
pumps. This and the data provided herein highlights the importance of strict monitoring
of silver use as an antimicrobial and administration of the appropriate dosages when used.
This study focused on the antimicrobial activity of silver acetate against the lesser
studied ESKAPE pathogen; A. baumannii. The data herein demonstrates a similar
trend in antimicrobial activity to this bacterial species as others have reported for
more widely studied pathogens including S. aureus with MIC’s in the range of
0.08–32 mg L−1, P. aeruginosa with MIC’s of 0.04–8 mg L−1 and Escherichia coli with
MIC’s of 0.5–2.5 mg L−1 (Peetsch et al., 2013; Zhang et al., 2015; Oates et al., 2018; Shah
et al., 2020).
As well as the concentration at which antimicrobials can inhibit growth or kill bacterial
pathogens another important property is the speed with which they are able to exert these
effects. Herein we have demonstrated that exponentially growing cultures suffered a
four-log reduction in viability at silver acetate concentrations similar to the minimal
bactericidal concentration within 2 h exposure. Higher concentrations of the silver salt
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showed almost complete cell death by this time (Fig. 2) and 6 h post-exposure
concentrations >7.81 mg L−1 caused a complete loss of viability. Other studies have also
demonstrated both a time and concentration dependent killing of bacteria upon exposure
to silver (Jaime-Acuña et al., 2016). Here, a silver-based nanocomposite was used to
demonstrate the time and concentration dependent killing of E. coli.
Besides antimicrobial activity, a key factor in determination of whether silver acetate is
suitable as an effective treatment for infection or prophylaxis is its toxicity to the host.
Selective toxicity has been a cornerstone of antimicrobial therapy since Paul Ehrlich
first proposed the concept by stating that the optimal agents would combine high
parasitotropism with low organotropism (Witkop, 1999). G. mellonella is increasingly
used as an ethically viable alternative to mammalian models for testing toxicity of
compounds to the host (Dolan et al., 2016; Aneja et al., 2018; Cruz et al., 2018; Lazarini
et al., 2018). One recent study compared the toxicity of exposure to eight different food
preservatives in both G. mellonella and rat models, concluding that there was a strong
correlation between the LD50 values of those preservatives in G. mellonella larvae and rats
providing evidence of the suitability of this model for preliminary toxicity testing
(Maguire, Duggan & Kavanagh, 2016).
In our study toxicity testing in the G. mellonella model revealed that only the highest
concentration of silver acetate tested (80 mg kg−1 animal weight) caused significant
death of the larvae. Therapeutic ranges of antimicrobials can be as low as 5 mg kg−1 daily to
up to 85 mg kg−1 for urinary tract infections caused by indwelling catheters (National
Institute for Health & Care Excellence, 2018). The dose depends on the administration
method and the severity of the infection; however, most doses administered are less
than 20 mg kg−1. As 10–20 mg kg−1 silver acetate showed no detrimental effects on the
larvae here, it can be concluded that these are safe therapeutic doses in this model.
Additionally, these low doses were able to significantly improve survival of the larvae after
infection with a carbapenem-resistant strain of A. baumannii providing promising data for
the clearance of drug-resistant bacterial pathogens.
The inoculum study revealed that ~106 bacterial cells per larvae were able to cause 80%
larval death, which is an appropriate amount of mortality for subsequent treatment studies
(Ignasiak & Maxwell, 2017). For comparison, a 10-fold lower infectious dose was also
tested. The survival of larvae injected with ~105 bacteria cells increased by 20% at both
concentrations of silver acetate used to treat the infection, while for the 10-fold higher
infectious dose, survival increased by 27% and 31% for treatment with 20 and 10 mg kg−1
doses respectively. Future research could utilise this statistically significant improvement
in survival upon administration of silver acetate in combination with antibiotic treatment
to look for increased antimicrobial activity. Previous studies have demonstrated the
potential synergy of silver ions with established antibiotics of the β-lactam, quinolone and
aminoglycoside groups (Morones-Ramirez et al., 2013). More recently, silver nanoparticles
have demonstrated synergy and additive effects when used in conjunction with antibiotics
including kanamycin and chloramphenicol respectively (Vazquez-Muñoz et al., 2019).
Here, membrane disruption was identified as a mechanism of action that improved
antibiotic activity by allowing improved access to intracellular targets for these antibiotics.
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Further study of the adjuvant effects of silver acetate against drug resistant bacterial
pathogens when administered alongside antibiotics currently on the market could provide
a new route to antimicrobial treatment of these pathogens.
In conclusion the data presented here demonstrates the efficacy of silver acetate as an
antimicrobial against carbapenem resistant A. baumannnii. We demonstrate that this
silver salt is non-toxic to G. mellonella at concentrations able to cause significant
antimicrobial activity and further that the administration of silver acetate can improve
survival of infected larvae. Together this data suggests silver acetate is a suitable silver salt
candidate for antimicrobial therapy when administered at an appropriate concentration.
CONCLUSIONS
Herein we sought to determine the antimicrobial efficacy of silver acetate against a
carbapenem resistant strain of A. baumannii both in vitro and in an in vivo G. mellonella
infection model. We found that silver acetate had bactericidal effects on the pathogen, was
able to reduce biofilm formation and was able to significantly improve the survival of
G. mellonella infected with otherwise lethal doses of A. baumannii. This data shows that
silver acetate may be used as an effective antimicrobial at concentrations that are not
damaging to the host and support the hypothesis that it can be used in efficacious
antimicrobial therapy.
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